Skip to main content

Day: August 13, 2025

Wesdome Reports Second Quarter 2025 Financial Results

TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) — Wesdome Gold Mines Ltd. (TSX: WDO, OTCQX: WDOFF) (“Wesdome” or the “Company”) today announced its financial results for the three and six months ended June 30, 2025 (“Q2 2025” and “H1 2025”). Preliminary operating results for Q2 2025 were disclosed in the Company’s press release dated July 14, 2025. Management will host a conference call tomorrow, August 14, 2025 at 10:00 a.m. ET to discuss its results. All amounts are expressed in Canadian dollars unless otherwise indicated. HighlightsImproving Safety Performance: Total Classified Incident Frequency Rate was 0.00 in Q2 2025 and 0.19 for H1 2025, a significant improvement from the 2024 average of 1.34. Production and costs: Consolidated gold production was 42,781 ounces; a 3% decrease compared to Q2 2024. Cost of sales per ounce sold...

Continue reading

Orchid Island Capital Announces August 2025 Monthly Dividend and July 31, 2025 RMBS Portfolio Characteristics

August 2025 Monthly Dividend of $0.12 Per Share of Common Stock RMBS Portfolio Characteristics as of July 31, 2025 Next Dividend Announcement Expected September 8, 2025VERO BEACH, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) — Orchid Island Capital, Inc. (the “Company”) (NYSE: ORC) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of August 2025. The dividend of $0.12 per share will be paid September 29, 2025 to holders of record of the Company’s common stock on August 29, 2025, with an ex-dividend date of August 29, 2025. The Company plans on announcing its next common stock dividend on September 8, 2025. The Company intends to make regular monthly cash distributions to its holders of common stock. In order to qualify as a real estate investment trust (“REIT”), the Company must...

Continue reading

LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Announced entry into an agreement to be acquired by XOMA Royalty Corporation for between $1.16 and $1.24 per share in cash, plus a contingent value right related to LAVA’s two partnered assets and unpartnered programs Consummation of acquisition expected to occur in the fourth quarter of 2025, subject to customary closing conditions and an extraordinary general meeting of shareholders Announced decision to discontinue development of LAVA-1266 for acute myeloid leukemia and myelodysplastic syndrome; wind-down of the program has been initiatedUTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 (GLOBE NEWSWIRE) — LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” or the “Company”), a clinical-stage immuno-oncology company historically focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced...

Continue reading

Global Water Resources Reports Second Quarter 2025 Results

PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) — Global Water Resources, Inc. (NASDAQ: GWRS), a pure-play water resource management company, reported results for the second quarter ended June 30, 2025. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 1:00 p.m. Eastern time tomorrow to discuss the results (see dial-in information below). Q2 2025 Financial HighlightsTotal revenue increased 5.4% to $14.2 million, primarily due to organic connection growth, increased consumption and higher rates. Net income decreased to $1.6 million or $0.06 per share from $1.7 million or $0.07 per share. One of the primary drivers of this decline is due to the company’s capital improvement plan, which has resulted in a related increase in depreciation expense. Adjusted EBITDA, a non-GAAP...

Continue reading

Astrotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference in September 2025

AUSTIN, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) today announced that Thomas B. Pickens III, Chairman and Chief Executive Officer, and Jennifer Cañas, Chief Financial Officer, will host investor meetings on Tuesday, September 9, 2025 as part of the H.C. Wainwright 27th Annual Global Investment Conference in New York City taking place at the Lotte New York Palace Hotel. Investors can register and request meetings with management via their HC Wainwright representative or Astrotech Investor Relations at mkreps@darrowir.com. About Astrotech Corporation Astrotech Corporation is a mass spectrometry company that creates, operates, and scales innovative businesses through its wholly owned subsidiaries. Each subsidiary leverages Astrotech’s core technology to serve specialized...

Continue reading

Brookfield Corporation Announces Pricing of $650 Million Notes Due 2036

BROOKFIELD, NEWS, Aug. 13, 2025 (GLOBE NEWSWIRE) — Brookfield Corporation (“Brookfield”) (NYSE: BN, TSX: BN) today announced the pricing of a public offering of $650 million principal amount of senior notes due 2036 (the “notes”), which will bear interest at a rate of 5.330% per annum. The offering is expected to close on August 20, 2025, subject to the satisfaction of customary closing conditions. The notes will be issued by Brookfield Finance Inc., an indirect wholly-owned subsidiary of Brookfield, and will be fully and unconditionally guaranteed by Brookfield. It is expected that the net proceeds from the sale of the notes will be used for general corporate purposes. The notes are being offered under Brookfield and the issuer’s existing base shelf prospectus filed in the United States and Canada and pursuant to an effective...

Continue reading

Gulf Resources, Inc. Announces Second Quarter 2025 Unaudited Financial Results

SHOUGUANG, China, Aug. 13, 2025 (GLOBE NEWSWIRE) — Gulf Resources, Inc. (Nasdaq: GURE) (“Gulf Resources,” “we,” or the “Company”), a leading manufacturer of bromine, crude salt and specialty chemical products in China today announced its unaudited financial results for the three months ended June 30, 2025. The company reported:Net Revenue increased by 250% to $8,343,785 from $2,383,169 in the previous year. Gross profits increased to $986,655 from a loss of $2,728,889. The loss from operations was $750,686 compared to a loss of $5,146,997. The net loss was $773,777 versus a net loss of $33,097,918 in the previous period. The Loss per share was $0.06 versus a loss of $3.09 in the previous period. Negative cash flow for the 6 months of 2025 was sharply reduced from $61,856,355 to $2,339,081.On a segment basis BromineBromine...

Continue reading

Planet 13 Announces Q2 2025 Financial Results

Q2 2025 Revenue of $26.9 millionQ2 2025 Net loss of $13.3 millionQ2 2025 Adjusted EBITDA loss of $2.4 millionAll figures are reported in United States dollars ($) unless otherwise indicated LAS VEGAS, Aug. 13, 2025 (GLOBE NEWSWIRE) — Planet 13 Holdings Inc. (CSE: PLTH) (OTCQX: PLNH) (“Planet 13” or the “Company”), a leading vertically-integrated multi-state cannabis company, today announced its financial results for the three-month period ended June 30, 2025. Planet 13’s financial statements are prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”). “Q2 played out in a tough operating environment. Against that backdrop, we remained sharply focused on what we can control, driving efficiencies and cutting costs. At the same time, we took bold steps to maximize our scale advantage in Nevada, moving...

Continue reading

SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical hold, triggering a $10M milestone payment from GSK. An additional $20M milestone will be triggered upon the six month anniversary of the new patient dosing; as previously disclosed GSK disputes these milestone payments.  SCYNEXIS vigorously disagrees with GSK’s position and is working towards resolving this disagreement;SCYNEXIS is actively working with GSK to transfer the BREXAFEMME New Drug Application (NDA) to GSK by the end of this year, ahead of anticipated GSK Regulatory interactions in 2026 to discuss the relaunch of the product.The Company anticipates reporting Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) data for SCY-247 (oral) in Q3 2025Regarding the November 2023 securities class action, that was filed by Brian...

Continue reading

Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update

– Positive 12-month Phase 1/2 clinical data in adult cohort and early pediatric clinical data support potential for meaningful vision restoration with OPGx-LCA5 – – FDA grants Regenerative Medicine Advanced Therapy (RMAT) designation for OPGx-LCA5 – – Positive topline results reported from VEGA-3 and LYNX-2 Phase 3 trials with Phentolamine Ophthalmic Solution 0.75% – – OPGx-BEST1 on track to enter Phase 1/2 trial in H2 2025 for the treatment of bestrophin-1 related inherited retinal disease – – Non-dilutive funding from patient advocacy groups secured to advance multiple early-stage gene therapy programs – RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2025 (GLOBE NEWSWIRE) — Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.